CorMedix Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph Todisco
- Full Time Employees
- 191
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 389 Interpace Pkwy Parsippany NJ United States of America 07054
- IPO Date
- May 13, 2010
- CIK
- 0001410098
- Website
- cormedix.com
- Similar Companies
- Business
- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory diseases, primarily targets hospital and dialysis settings in the United States with expanding international presence. Founded in 2006 and headquartered in Berkeley Heights, New Jersey, the company offers DefenCath (taurolidine and heparin catheter lock solution), the first and only FDA-approved antimicrobial therapy to reduce catheter-related bloodstream infections in adult hemodialysis patients via central venous catheters; following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix also commercializes an expanded portfolio of anti-infective products including MINOCIN (minocycline for infections), REZZAYO (rezafungin for candidemia and invasive candidiasis), VABOMERE (meropenem and vaborbactam for urinary tract and complicated intra-abdominal infections), ORBACTIV (oritavancin for acute bacterial skin and skin structure infections), BAXDELA (delafloxacin for skin infections and community-acquired bacterial pneumonia), KIMYRSA (oritavancin for bloodstream and skin infections), and TOPROL-XL (metoprolol succinate for cardiovascular conditions). The company conducts ongoing clinical studies for DefenCath in total parenteral nutrition, pediatric, and oncology patient populations, while REZZAYO advances in a Phase III trial for prophylaxis of invasive fungal infections in allogeneic blood and marrow transplant patients, with topline results expected in Q2 2026. Recent developments include the transformative September 2025 completion of the Melinta Therapeutics acquisition, which diversifies the product portfolio, raises pro forma 2025 revenue guidance to $325-350 million, projects annual synergies of $35-45 million, and introduces enhanced leadership in hospital acute care; in October 2025, DefenCath earned Innovative Technology Designation from Vizient for its clinical impact on infection prevention; third-quarter 2025 results reported $104.3 million in net revenue and $130.8 million pro forma, driven by commercial launches and market penetration.
Company News
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CorMedix (CRMD) Upgraded to Buy: Here's Why
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Q2 Earnings Call Highlights
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms